Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
dopamine agonist |
| gptkbp:CASNumber |
524-36-7
|
| gptkbp:chemicalFormula |
C10H13N3
|
| gptkbp:drugClass |
dopaminergic agent
|
| gptkbp:effect |
induces compulsive behavior in animal models
|
| gptkbp:hasSideEffectInAnimals |
anxiety-like behavior
hyperlocomotion stereotypy |
| https://www.w3.org/2000/01/rdf-schema#label |
quinpirole
|
| gptkbp:isNotApprovedFor |
human therapeutic use
|
| gptkbp:IUPACName |
8-(2-pyridinyl)-1,2,3,4-tetrahydro-1-naphthalenamine
|
| gptkbp:meltingPoint |
230-232°C
|
| gptkbp:molecularWeight |
175.23 g/mol
|
| gptkbp:PubChem_CID |
5018
CHEMBL1167 |
| gptkbp:routeOfAdministration |
subcutaneous injection
intraperitoneal injection |
| gptkbp:synonym |
LY 171555
quinpirole hydrochloride |
| gptkbp:targetsReceptor |
D2 dopamine receptor
D3 dopamine receptor |
| gptkbp:UNII |
Q7V2JZ55Z4
|
| gptkbp:usedInResearchOn |
gptkb:Parkinson's_disease
gptkb:obsessive-compulsive_disorder addiction |
| gptkbp:bfsParent |
gptkb:dopamine_receptor_D2
|
| gptkbp:bfsLayer |
7
|